Some four years into Jemperli’s commercial lifespan, a rift has emerged between GSK subsidiary Tesaro and the potential cancer blockbuster’s original developer, AnaptysBio. | Some four years into ...

AnaptysBio has separately alleged that GSK subsidiary Tesaro breached “certain requirements” under their 2014 license agreement involving a program that would become GSK's Jemperli.

GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks deal ...

Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's ...

GSK has escalated a dispute over rights to its cancer immunotherapy Jemperli, after its subsidiary Tesaro filed a complaint ...

GSK teams with LTZ Therapeutics to co-develop next-gen myeloid-cell engager immunotherapies in oncology leveraging LTZ’s innate-immune platform and GSK’s development engine.

Just a few weeks after the company announced licensing agreements with Empirico and Syndivia, GSK announced a strategic ...

Analysts at Berenberg slightly raised their target price on drugmaker GSK from £16 to £16.60 per share on Tuesday after it hosted chief financial officer Julie Brown for the eighth session of its ...

After charting a similar move in Kenya last year, GSK is pulling the plug on its Nigerian operations. Late last week, GSK said it plans to cease commercialization of its prescription medicines and ...

We recently published 11 Stocks Crushing Wall Street With Whopping Gains. GSK plc (NYSE:GSK) is one of the top performers on Tuesday. Shares of GSK rallied for a third straight day on Tuesday to hit a ...